ANI Pharmaceuticals announces a recommended public offer to acquire Egetis Therapeutics for approximately $560 million, expanding its rare disease business.

The acquisition aims to leverage ANI's resources and expertise in rare diseases, strengthen its clinical development capabilities, and diversify its revenue base. Egetis Therapeutics is a commercial-stage pharmaceutical company focused on rare disease therapies. The offer values Egetis at SEK 11.25 per share, a 27% premium to its 60-day volume-weighted average price.